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compare return to baseline (RTB) for HRQoL. A seven point dif-
ference (considered to be clinically signiﬁcant) between baseline
and follow-up score was considered as RTB. RESULTS: ANOVA
indicated that RP group had higher scores for generic HRQoL
subscales of physical function (p = 0.019), role emotional (p =
0.037), vitality (p = 0.033) and general health (p = 0.05). Step-
wise log-linear regression models showed that RP was associated
with higher 12 month scores for most of the generic HRQoL
scales, bowel function (OR = 1.12), urinary bother (OR = 1.6)
and bowel bother (OR = 1.5). For generic HRQoL (SF-36) at 12
month follow-up, higher proportion of the RP group returned to
baseline on eight sub-scales. RP group had lower proportion
returning to baseline for urinary (p = 0.0012) and sexual (p =<
0.0001) functions, and higher proportion returning to baseline
for bowel function, urinary bother and bowel bother (p =<
0.005). Satisfaction with care was comparable between treat-
ment groups. CONCLUSIONS: Older patients appear to have
better tolerance for RP as indicated by patient reported 
outcomes. Thus age alone need not be a criterion in treatment
decision.
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EMOTIONAL WELL-BEING OF EARLY-STAGE PROSTATE
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OBJECTIVE: To compare self-reported satisfaction with care
and emotional well-being of newly diagnosed prostate cancer
(PCa) patients receiving either Radical Prostatectomy (RP) or
External Beam Radiation Therapy (EBRT). METHODS: The
study was part of a larger prospective cohort study. We recruited
231 newly diagnosed African-American and Caucasian PCa
patients from urology clinics of an urban academic hospital and
a VA hospital. Patients completed the Client Satisfaction Ques-
tionnaire (CSQ-8), SF-36, FACT-p and UCLA-PCI prior to their
treatment and at 3, 6, and 12 month follow-up. Demographic
and clinical data were obtained from hospital based databases.
Parametric and nonparametric tests were used to compare demo-
graphics, clinical characteristics and FACT-p subscales between
treatment groups. Log linear regression models were used to
assess factors associated with satisfaction. RESULTS: The RP
group was younger (p < 0.0001), had a higher proportion of
Caucasians (p < 0.0001), and were more like to be married (p <
0.0001), have incomes greater than $40,000 (p < 0.0001) and
be employed full-time (p < 0.0001). Gleason score, TNM stage
and Charlson comorbidity score were comparable by groups.
Higher number of EBRT group reported poorer outcome mea-
sures on emotional well being subscale of FACT-p, compared to
RP group. A higher proportion of RP patients indicated that they
were likely to recommend the treatment to a friend (p = 0.0244)
and that they would seek the same treatment if needed again 
(p = 0.0328). ANOVA of total CSQ8 score indicated signiﬁcant
differences between the groups and over time (p = 0.0059 and
0.0228, respectively). Log linear regression showed that RP
treatment (OR = 1.13, p = 0.045), baseline PSA (OR = 0.98, 
p = 0.0062) and VA hospital (OR = 0.84, p = 0.0299) were asso-
ciated with total satisfaction with care. CONCLUSION: EBRT,
higher baseline PSA and non-VA hospital type are associated
with lower satisfaction with care of PCa patients at 12 months
post-treatment.
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OBJECTIVE: Exploring impact of NSCLC on quality of life
(QOL) by eliciting utilities from a community sample. Non-small
cell lung cancer (NSCLC) and its treatment both have a sub-
stantial negative effect on QOL. Little published research quan-
tiﬁes these effects in advanced disease. METHODS: Health state
descriptions were developed from the literature and reﬁned
through clinician interviews (n = 6). Treatment response, stable
disease, progressed disease, near-death and adverse events (AEs):
neutropenia, febrile neutropenia, nausea, diarrhoea, stomatitis,
neuropathy and rash were described. The impact of oral versus
intravenous (IV) medication was also explored. A total of 154
lay people across the UK (Glasgow, Oxford, London, Cardiff)
were presented with information on NSCLC. Health states, pre-
sented randomly, were valued using the EQ-5D. These values
were converted to utilities for each health state. RESULTS: All
health states were associated with low utility values. The utility
value for near-death was the lowest (0.15) and that for treatment
response the highest (0.49). There was no statistical difference
between treatment response and stable disease (0.46). Stable
disease receiving IV therapy had a signiﬁcantly lower utility
(0.43) than stable disease with no treatment; stable disease
receiving oral therapy (0.45) did not. The utility value associated
with progressed disease (0.22) was closer to that for near-death.
Utilities for AEs were valued relative to the stable disease state.
The greatest disutility was associated with febrile neutropenia 
(−0.27) and the lowest with rash (−0.06). Disutilities associated
with other AEs were neuropathy (−0.15), neutropenia (−0.14),
nausea (−0.14), stomatitis (−0.14) and diarrhoea (−0.13). CON-
CLUSIONS: Societal valuation showed that all disease states and
AEs associated with NSCLC have a substantial impact on QOL,
with disease progression, febrile neutropenia and near-death
having the greatest impact. Treatment related rash is the least
serious adverse event. Stable disease is associated with a better
QOL than progressed disease.
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OBJECTIVES: Human Papillomavirus (HPV) is a necessary
cause of cervical cancer (CC). To date, CC screening programmes
have been the only tool to help to prevent CC by detecting and
removing precancerous lesions. With the expected licensure of a
quadrivalent HPV vaccination, a decision analysis model was
developed to quantify the health and economic beneﬁts of a
quadrivalent (6, 11, 16, 18) HPV vaccine alongside CC screen-
ing in Switzerland. METHODS: The vaccine was considered to
prevent 100% of HPV 6, 11, 16 and 18-associated diseases, with
lifetime duration of protection and 40% coverage rate, when
given to girls at age 12. Resource consumption included physi-
cian visits, medical examinations, treatments and hospitalisa-
tions. Data for management of abnormal pap smears, cervical
dysplasia and genital warts were estimated by Swiss experts.
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Lifetime risks data were extrapolated from a published Markov
model. Screening and population data were extracted from ofﬁ-
cial references. Costing was assessed through the compiled 5 year
activities of a gynaecologic department (CHUV, Lausanne),
TARMED (2005) and Compendium (2005). Sensitivity analyses
examined vaccine parameters, range of treatment patterns and
costs. RESULTS: For a 12 year old cohort of girls with 40%
vaccine coverage rate, the model predicts a lifetime reduction of
22% of CC and related deaths, −23% of CIN 2/3, −11% for
CIN 1 and −36% for genital warts. The associated increase in
the national health care budget was only 3% (+4,5 million CHF).
If vaccine coverage rate reached 80%, clinical impact on CC
would be more than 50% better whilst increasing the budget by
only 6%. Results are robust to sensitivity analyses. CONCLU-
SION: Preventing HPV related diseases through vaccination with
a quadrivalent (6, 11, 16, 18) HPV vaccine alongside CC screen-
ing in Switzerland could result in signiﬁcant clinical beneﬁts with
only a slight increase on the national health care budget.
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OBJECTIVES: To assess the potential epidemiological, clinical,
and economic effects of different varicella vaccination strategies
in Italy, involving children and adolescents. METHODS: The
simulation model EVITA (Banz et al. 2003) was developed to
analyse universal varicella vaccination strategies. Epidemiologi-
cal and economic model input data were collected from Tuscany
region data banks and the available Italian literature. The vac-
cination strategies analysed included: 1) 1–1.5 y (years), 85%
coverage; 2) 1–1.5 y + catch-up 12 y (1 dose, 30% catch-up cov-
erage); 3) 1–1.5 y + catch-up 13 y (2 doses, 30% coverage); and
4) 1–1.5 y with 2 doses + catch-up 13 y (2 doses, 30% coverage).
Analysis time horizon was 30 years. RESULTS: Without univer-
sal vaccination, the model predicted 501.644 varicella cases and
27.341 related complications in Italy each year. All vaccination
strategies resulted in excellent clinical outcomes, with strategy 2)
being the most effective, preventing over 83% of varicella cases
and complications. A low coverage scenario (50%) prevented
only 68% of varicella cases, with a rebound of cases occurring
after around 15 years of initial decline. Average yearly cost
savings for strategy 2) are 62 million Euros for the society and 2.3
million Euros for the NHS, and for the 1) strategy 59.7 and 2.5
million Euros, respectively. The most favourable clinical and eco-
nomic outcomes of a catch-up programme occurred when vac-
cinating 12 y adolescents with 1 dose instead 13 y adolescents
with 2 doses. Only strategy 4) failed to generate savings for the
NHS. No signiﬁcant differences in outcomes were detected when
using epidemiological and seroprevalence data corresponding to
North, Centre and South of Italy. CONCLUSIONS: Universal
varicella vaccination in children (with or without an adolescent
catch-up programme) is very effective in reducing the high
burden of disease and leads to signiﬁcant cost savings.
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TREATMANT, SRBIJA, NIS REGION
Mihajlovic MM1, Nikolic S2
1City Pharmacy Nis, Nis,Yugoslavia, 2Government Primary Health
Care Institution, Nis, Serbia, Serbia and Montenegro
OBJECTIVES: Identiﬁcation of cost–effectivness antibiotic treat-
ment method tonsilopharyngitis and rhynopharingitis accuta in
pediatric population from just born to 12 years old children in
which these diagnosis were establish on the level of private and
government primary health care practice system, depending of
clinical report and possible drug hypersensitivity. METHODS:
Cost–effectiveness analysis was done in two different periods of
time; The ﬁrst one was before establishing “The National guide
for antibiotic treatment”, and the second one after that. Four
possible treatments with 30 children each were observed. These
are following–before the implementation of the National guide
1) Phenoxymethylpenicillin oral suspension (300,000 IJ/5 ml 10
days); 2) Erythtomycin oral suspension (200 mg/5 ml 5 days); 3)
Benzylpenicilin procainpennicillin inj i.m. (800,000 IJ 7 days); 4)
Lincomycin inj i.m (600 mg/2 ml 7 days). After 1) Amoxicilin +
clavulonic acid oral suspension (7 days); 2) Azirohromycin oral
suspension (200 mg/5 ml 4 days), 3) Benzylpenicillin procain-
penicillin inj i.m.; 4) Phenoxymethlpenicillin oral suspension.
Real costs were calculated for each possible treatment contains
direct (ﬁrst doctor visit, control check up, medicines and OTC
therapy costs), indirect (additional treatment payment and even-
tual complication payment). Patients were sorted in those with
completely, partly successful and total unsuccessful treatment.
ICER (Incremental cost effectivness ratio) was deﬁned for each
possible treatment; base was number of days without refreshing
infection. Comparison of ICER value gave cost effectivness
therapy. RESULTS: ICER showed for the ﬁrst period that Ben-
zylpenicillin procainpenicillin inj i.m. (7 days) was the best cost
effectivness treatment. In addition The National guide conﬁrmed
and recommended it also. On the contrary, after implementation
of the National guide the most prescribing treatments were
Amoxicilin+clavulonic acid oral suspension (7 days) and Phe-
noxymethlpenicillin oral suspension (10 days). It doesn’t reduce
therapy costs. CONCLUSIONS: Prescribing practice in Serbia
should be changed by using the most CE methods and that will
cause decrease in total costs of antibiotic therapy.
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OBJECTIVES: To determine the cost-effectiveness of meropenem
treatment versus standard strategy of antibiotic (AB) therapy for
high-risk patients with nosocomial infection (NI) in the intensive
care unit (ICU). METHODS: Two group high-risk patients with
NI were randomly assigned to AB treatment: 1st—62 pts received
meropenem (1.5–3 g daily) and 2nd—73 pts treated by standard
AB therapy (combination of penicillins with or without a beta-
lactamase inhibitor, cephalosporins III or IV generation, ﬂuoro-
quinolons with aminoglicosides). Direct medical costs (cost of
drag administration, resource utilization, duration of hospital-
ization) were estimated. Achievement of recovery was used as
effectiveness. Unit costs were based on detailed data from the
Moscow Obligatory Insurance Fond (2006). The rate of exchange
was 34,44 rubles for 1 EUR. RESULTS: Direct medical costs were
1618.6 EUR for group 1 (C1) and 2065.7 EUR for group 2 (C2).
Achievement of recovery −80.6% (E1) and 46.6% (E2) for each
group respectively, p < 0,01. The ﬁnal calculation of cost/effec-
tiveness ratio (CER) was: CER1 = €20.08 and CER2 = €44.32
per every percent of recovered patients for group 1 and 2 respec-
tively. CONCLUSION: Meropenem usage versus standard AB
therapy is more effective from the position “cost-effectiveness”
in the treatment of high-risk patients with nosocomial infection
in the intensive care unit.
